KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Share-based Compensation (2018 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Share-based Compensation data on record, last reported at $1.4 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 42.74% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $7.6 million, up 7.4%, while the annual FY2025 figure was $7.6 million, 7.4% up from the prior year.
  • Share-based Compensation reached $1.4 million in Q4 2025 per AQST's latest filing, down from $2.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.8 million in Q3 2025 and bottomed at $344000.0 in Q1 2023.
  • Average Share-based Compensation over 5 years is $1.4 million, with a median of $1.6 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: crashed 71.84% in 2022, then surged 359.3% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $1.7 million in 2021, then tumbled by 57.78% to $714000.0 in 2022, then soared by 31.65% to $940000.0 in 2023, then soared by 155.64% to $2.4 million in 2024, then plummeted by 42.74% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $1.4 million in Q4 2025, $2.8 million in Q3 2025, and $1.9 million in Q2 2025.